ACRS Aclaris Therapeutics, Inc.

NASDAQ
$5.78

Aclaris Therapeutics, Inc. (ACRS) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.17 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.8% since its last earnings release on August 6, 2026.

Aclaris Therapeutics Beat Consensus Estimates
Thursday, August 6, 2026 · 6:59 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.17)
Rev est $1.41M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.94

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow